Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-277 SAD Study in Healthy Adults
NCT07136103Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised trial of ABBV-277 (10 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration at 9 days, Time to Cmax at 9 days and 5 more. Started Aug 2025; status: completed.
02
Drugs
ABBV-277
Beyond the preview
Go deeper on NCT07136103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136103.